Prior art — US Patent 11013729

The USPTO database search for patent number 11013729 reveals several prior art documents cited by the examiner. These citations are crucial for understanding the novelty and inventiveness of US Patent 11013729.

Here is an analysis of the most relevant prior art documents cited in US Patent 11013729:

1. WO 1998/037075 A1

Full Citation: WO1998/037075A1 - Disubstituted bicyclic heterocycles, their production and use as medicaments.
Publication Date: August 27, 1998.
Brief Description: This patent first disclosed dabigatran, claiming compounds with a thrombin-inhibiting effect and the effect of prolonging thrombin time. It describes the chemical compound 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-ylcarboxylic acid-N-(2-pyridyl)-N-(2 ethoxycarbonylethyl)amides, which is dabigatran.
Potential Anticipation (35 U.S.C. § 102): This reference anticipates the active pharmaceutical ingredient (dabigatran etexilate) itself and its general therapeutic use as a direct thrombin inhibitor. It would likely anticipate any claim in US11013729 that broadly covers dabigatran etexilate as an active agent without specifying the unique two-particle formulation. Claims 1, 11, and 16, to the extent they merely identify dabigatran etexilate as an active ingredient, could be considered anticipated by this foundational disclosure.

2. US 2006/0183779 A1

Full Citation: US 2006/0183779 A1 - Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof.
Publication Date: August 17, 2006.
Brief Description: This patent application describes pharmaceutical compositions of dabigatran etexilate mesylate (DEM) for oral administration in the form of pellets. These pellets comprise a core of one or more pharmaceutically acceptable organic acids (e.g., tartaric acid) and an active substance layer containing DEM, which encloses the core. It also mentions a separating or insulating layer between the acid core and the active substance layer, and an optional outer coating to increase abrasion resistance and shelf life.
Potential Anticipation (35 U.S.C. § 102): This reference is highly relevant to US11013729, particularly to claims involving separate acid components and protective coatings. Claims 1, 11, and 16, which describe a composition with a first type of particles (dabigatran etexilate) and a second type of particles (organic acid coated with a protective layer), could be seen as building upon the concept of separating the active ingredient from the acid core. However, US11013729 explicitly states that its "first type of particles comprise dabigatran etexilate... wherein the first type of particles is free from organic acids and inorganic acids". In contrast, US 2006/0183779 A1 describes the active substance layer enclosing the acid core. The key distinction for US11013729 may lie in the complete separation of the active ingredient and the acid into distinct particles, with the organic acid particles themselves being coated. This distinction might protect claims 1, 11, and 16 from direct anticipation, but the overall concept of using an acid to enhance dissolution and using coated particles for stability is clearly present in this prior art.

3. US 2005/0038077 A1

Full Citation: US 2005/0038077 A1 - Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof.
Publication Date: February 17, 2005.
Brief Description: This patent discloses a tablet composition comprising dabigatran etexilate or its pharmaceutically acceptable salt, one or more pharmaceutically acceptable organic acids, and a pharmaceutically acceptable excipient or filler. The patent highlights a drawback: without special separation steps, the active ingredient in such a tablet composition can be highly susceptible to hydrolysis in the presence of humidity due to the close contact with the organic acid.
Potential Anticipation (35 U.S.C. § 102): This reference anticipates compositions that combine dabigatran etexilate and an organic acid in a single dosage form (tablet). Claims 1, 11, and 16 of US11013729 differentiate themselves by specifying two distinct types of particles with the active agent being free from acids and the organic acid particles being coated. This design in US11013729 aims to overcome the stability issues identified in US 2005/0038077 A1 where the active and acid are in close contact. Therefore, while the components are similar, the structural arrangement claimed in US11013729 appears to be a solution to a problem recognized by this prior art, rather than a direct anticipation.

4. WO 2005/028468 A1

Full Citation: WO2005/028468A1 - 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament.
Publication Date: March 31, 2005.
Brief Description: This patent describes the anhydrous polymorphic forms I and II of dabigatran etexilate mesylate (DEM).
Potential Anticipation (35 U.S.C. § 102): This reference anticipates the specific polymorphic forms of dabigatran etexilate mesylate. Claims 1, 11, and 16 of US11013729 refer to "dabigatran etexilate in the form of the free base or in the form of a pharmaceutically acceptable salt or polymorph thereof." The disclosure of specific polymorphs in WO 2005/028468 A1 would mean that any claim in US11013729 that relies solely on the existence of these polymorphs of dabigatran etexilate mesylate without further structural or compositional limitations would be anticipated. However, US11013729's claims are focused on the two-particle composition rather than the specific polymorphic forms themselves.

Other cited references (less direct anticipation based on patent's claims):

US6087380A (Publication Date: 2000-07-11, Assignee: Boehringer Ingelheim Pharma Kg, Title: Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions). This patent also pertains to the broader class of compounds including dabigatran.
JPH04103525A (Publication Date: 1992-04-06, Assignee: Sanwa Kagaku Kenkyusho Co Ltd, Title: Production of sustainable pharmaceutical preparation for poorly water-soluble medicine). This patent describes methods for producing sustained-release preparations for poorly water-soluble medicines, but it does not specifically mention dabigatran etexilate or the two-particle system with a coated acid component.
WO1998050019A1 (Publication Date: 1998-11-12, Assignee: Sage Pharmaceuticals, Inc., Title: Stable oral pharmaceutical dosage forms). This general disclosure on stable oral pharmaceutical dosage forms does not appear to directly anticipate the specific two-particle system of US11013729.
WO2000012064A1 (Publication Date: 2000-03-09, Assignee: Andrx Pharmaceuticals, Inc., Title: Omeprazole formulation). This patent is for an omeprazole formulation and is not directly related to dabigatran etexilate.
JP2002316923A (Publication Date: 2002-10-31, Assignee: Tanabe Seiyaku Co Ltd, Title: Tablet rapidly disintegrable in oral cavity). This patent focuses on rapidly disintegrating tablets and does not disclose the specific two-particle composition of US11013729.
CA2476054A1 (Publication Date: 2003-09-12, Assignee: Boehringer Ingelheim Pharma Gmbh & Co. Kg, Title: Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof). This is another patent application from Boehringer Ingelheim concerning dabigatran formulations, likely related to the foundational disclosures.
WO2005046663A1 (Publication Date: 2005-05-26, Assignee: Shire Laboratories, Inc., Title: Compositions of quaternary ammonium containing bioavailability enhancers). This patent discusses bioavailability enhancers and is not directly related to the specific composition of US11013729.
WO2005121102A2 (Publication Date: 2005-12-22, Assignee: Pharmacyclics, Inc., Title: Factor viia inhibitor). This patent concerns a Factor VIIa inhibitor and is not for dabigatran etexilate.
US20060074056A1 (Publication Date: 2006-04-06, Assignee: Methylgene, Inc., Title: Inhibitors of VEGF receptor and HGF receptor signaling). This patent is for a different therapeutic area.
WO2007092026A1 (Publication Date: 2007-08-16, Assignee: Teva Pharmaceutical Industries Ltd., Title: Dipyridamole extended-release formulations and process for preparing same). This patent is for dipyridamole and extended-release formulations, not directly relevant to the dabigatran etexilate composition of US11013729.
US20080069891A1 (Publication Date: 2008-03-20, Assignee: Cima Labs, Inc., Title: Abuse resistant drug formulation). This patent concerns abuse-resistant drug formulations, not directly the dabigatran etexilate composition of US11013729.
CN101632668A (Publication Date: 2010-01-27, Assignee: 贝林格尔英格海姆法玛两合公司, Title: Oral pharmaceutical composition). This Chinese patent application from Boehringer Ingelheim is likely a counterpart or related to their other dabigatran disclosures.
US20110129538A1 (Publication Date: 2011-06-02, Assignee: Boehringer Ingelheim International Gmbh, Title: Process for preparing orally administered dabigatran formulations). This patent concerns processes for preparing dabigatran formulations and could be broadly relevant to manufacturing aspects, but its specific relevance to the compositional claims of US11013729 would depend on the details of the processes described.
WO2012001156A2 (Publication Date: 2012-01-05, Assignee: Krka, Tovarna Zdravil, D.D., Novo Mesto, Title: Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts). This patent describes other oral dosage forms of dabigatran etexilate, indicating continued development in this area prior to US11013729.The USPTO database search for patent number 11013729 reveals several prior art documents cited by the examiner. These citations are crucial for understanding the novelty and inventiveness of US Patent 11013729.